STING1 and neoplasm: Compared with previous nanodelivery systems, which often suffer from insufficient tumor targeting, limited STING activation, and lack of synergy with epigenetic modulators or PROTACs, our platform overcomes these limitations by integrating precise tumor targeting, combinatorial DNA damage, immune activation, and PROTAC‐enhanced checkpoint modulation into a single system.